Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S.
Abbott announced today that the U.S. Food and Drug Administration (FDA) has cleared the FreeStyle® Libre 2 iOS application for use with compatible iPhones(1), providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms(2). 
CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, announced it has signed a contract with the five regions within the Danish health authority for CSAM’s Prosang blood, cell, and tissue management system for blood banks. In an agreement between CSAM and all five health regions, the new contract will translate to approximately NOK 75-100 million NOK over at the next six years and will be implemented in all blood banks in the country. 
Fujitsu in the UK has announced its support of the AWS for Health initiative from Amazon Web Services (AWS) by bringing Epic in the Cloud to NHS trusts and UK healthcare providers.
The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. 
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform. 
Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it could - and should - mean for health tech.